Takeda International is a global pharmaceutical company headquartered in Japan. It’s top selling product, Actos, improves the body’s insulin use; while it also reduces blood sugar levels. In 1998 Takeda entered into a marketing partnership with Eli Lilly and Co. to push Actos in the United States and obtain FDA approval. Remarkably, one year later Actos was approved for release in the U.S. market and Takeda set up shop in Deerfield, Illinois, its U.S. corporate headquarters. Actos has been a huge success for Takeda, as Both Takeda and Eli Lilly marketed the drug in Japan, the United States, France and Germany. In 2010, Takeda’s global sales revenue from Actos was an estimated $4.8 billion with an estimated 2.3 million prescriptions filled in the United States. Recently Takeda has been on the defensive. In 2011 researchers determined that users of Actos are at an increased risk of bladder cancer. And , the top-selling drug is now the center of hundreds of lawsuits with Takeda as their target.